ARMP (Armata Pharma) שולי רווח גולמי

Armata Pharmaceuticals (ARMP) is developing phage therapy for hospitals, targeting the resistant lung pathogen segment. The change in gross profit margin on this GURU.Markets platform chart demonstrates the model's efficiency, where 73.00 shows the value of this parameter. Success depends on biologics regulation and funding. The company is currently scaling its R&D platform, progressing through mid-stage trials with support from funds.
פילוחי מדדים מקיפים ואנליטיקה עבור Armata Pharma (ARMP)

Gross margin measures the portion of revenue remaining after paying direct production costs, allowing for an assessment of the internal efficiency of operational processes and capital resilience. For Armata Pharmaceuticals (ARMP) in the bacteriophage therapy segment, the gross profit margin reflects the company's ability to monetize the fight against resistant infections, where an upward trend confirms the high value of its assets.